Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22651217 | 0.74 | PI4KA (0.30) | — | |
| SCHEMBL4923588 | 0.73 | PI4KA (0.47) | AXLMKNK2MAPTLMNAALDH1A1 | |
| SCHEMBL22907635 | 0.68 | AADAT (0.32) | — | |
| SCHEMBL12395092 | 0.68 | AADAT (0.30) | — | |
| SCHEMBL14627413 | 0.67 | AXL (0.31) | AXL | |
| SCHEMBL29991254 | 0.64 | PI4KA (0.57) | AXLMKNK1MKNK2SMN1; SMN2MAPT | |
| SCHEMBL17200301 | 0.62 | AXL (0.48) | AXLMKNK1MKNK2ALDH1A1 | |
| SCHEMBL30278653 | 0.62 | AXL (0.48) | AXLMKNK1MKNK2ALDH1A1 | |
| SCHEMBL29991404 | 0.62 | AXL (1.00) | AXLMKNK1MKNK2KMT2APDE4A | |
| SCHEMBL659673 | 0.62 | AXL (1.00) | AXLMKNK1MKNK2KMT2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562014-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026479-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026479-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3860990-B1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2022-09-14 | — | — | EP | disclosed |
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2021-10-21 | — | — | US | disclosed |
| EP-3860990-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Inventiva (FR) | 2021-08-11 | — | — | EP | disclosed |
| CN-113039182-A | Inhibitors of YAP/TAZ-TEAD interaction and their use in cancer treatment | 伊文蒂瓦公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2020070181-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | AXL 1035/4885MKNK1 837/4885MKNK2 650/4885 |
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | YAP1, TEAD2, YES1 | AXL 1317/4885MKNK1 286/4885MKNK2 293/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | AXL 1317/4885MKNK1 286/4885MKNK2 293/4885 |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK1 | AXL 903/4885MKNK1 805/4885MKNK2 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.